Press release
Bullous Pemphigoid Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | AstraZeneca, AKARI Therapeutics, Regeneron Pharmaceuticals, Argenx
DelveInsight's "Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as well as the Bullous Pemphigoid market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Bullous Pemphigoid market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Bullous Pemphigoid market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bullous Pemphigoid Market Forecast
https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bullous Pemphigoid Market Report:
• The Bullous Pemphigoid market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2022, the number of diagnosed prevalent cases of Bullous pemphigoid in the 7MM was approximately 134,000, with a projected increase by 2032.
• In 2022, within the 7MM, the United Kingdom recorded the highest number of diagnosed prevalent cases of Bullous Pemphigoid, totaling around 26,000, with anticipated growth by 2032.
• In 2022, there were approximately 145,000 treated cases of BP across the 7MM. According to evaluations by DelveInsight analysts, these treated cases are predicted to rise by 2032.
• According to DelveInsight's projections, in 2022, the diagnosed prevalent cases of Bullous Pemphigoid in the US varied across age groups, with approximately 1,000, 2,600, 10,900, and 12,900 cases among individuals aged 18-40 years, 41-60 years, 61-80 years, and over 80 years, respectively. These numbers are anticipated to increase by 2032.
• Key Bullous Pemphigoid Companies: AstraZeneca/Kyowa Kirin, argenx, Regeneron/Sanofi, Mayo Clinic, University of Iowa, Nihon Pharmaceutical, Duke University, Immune Pharmaceuticals, AKARI Therapeutics, and others
• Key Bullous Pemphigoid Therapies: FASENRA (benralizumab), DUPIXENT (dupilumab), Ixekizumab, efgartigimod PH20 SC, Omalizumab, NPB-01, Rituximab, Bertilimumab, rVA576, and others
• The Bullous Pemphigoid epidemiology based on age-specific cases analyzed that Bullous Pemphigoid is more prevalent in older age group (66 to 83 years)
Get a Free sample for the Bullous Pemphigoid Market Report -
https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bullous Pemphigoid Overview
Bullous pemphigoid is a rare, chronic autoimmune skin disorder characterized by large, fluid-filled blisters (bullae) that primarily appear on areas of the skin that often flex, such as the lower abdomen, upper thighs, or armpits. It most commonly affects older adults and can cause significant discomfort and itching.
Bullous Pemphigoid Market
The dynamics of the Bullous Pemphigoid market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Bullous Pemphigoid Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bullous Pemphigoid Epidemiology Segmentation:
The Bullous Pemphigoid market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bullous Pemphigoid
• Prevalent Cases of Bullous Pemphigoid by severity
• Gender-specific Prevalence of Bullous Pemphigoid
• Diagnosed Cases of Episodic and Chronic Bullous Pemphigoid
Download the report to understand which factors are driving Bullous Pemphigoid epidemiology trends @ Bullous Pemphigoid Epidemiological Insights
https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bullous Pemphigoid Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bullous Pemphigoid market or expected to get launched during the study period. The analysis covers Bullous Pemphigoid market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bullous Pemphigoid Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Bullous Pemphigoid treatment, visit @ Bullous Pemphigoid Medications
https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Bullous Pemphigoid Therapies and Key Companies
• FASENRA (benralizumab): AstraZeneca/Kyowa Kirin
• DUPIXENT (dupilumab): Regeneron/Sanofi
• Ixekizumab: Mayo Clinic
• efgartigimod PH20 SC: argenx
• Omalizumab: University of Iowa
• NPB-01: Nihon Pharmaceutical
• Rituximab: Duke University
• Bertilimumab: Immune Pharmaceuticals
• rVA576: AKARI Therapeutics
Bullous Pemphigoid Market Strengths
• The growth in the geriatric population, accompanied by a rise in the risk factors such as neurological disorders and the use of certain drugs (diuretics and neuroleptics), etc., over the globe, is resulting in an active rise in the prevalence of BP.
• The presence of precise diagnostic procedures and specific biomarkers ensures better diagnosis and prognosis for the disease patients.
Bullous Pemphigoid Market Opportunities
• The lack of approved therapies in the market presents a great opportunity for investment and the development of novel therapy.
• The current market for BP lacks therapies that address major challenges patients face, like a lack of medications with better safety for long-term use and low treatment duration.
Scope of the Bullous Pemphigoid Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bullous Pemphigoid AstraZeneca/Kyowa Kirin, argenx, Regeneron/Sanofi, Mayo Clinic, University of Iowa, Nihon Pharmaceutical, Duke University, Immune Pharmaceuticals, AKARI Therapeutics, and others
• Key Bullous Pemphigoid Therapies: FASENRA (benralizumab), DUPIXENT (dupilumab), Ixekizumab, efgartigimod PH20 SC, Omalizumab, NPB-01, Rituximab, Bertilimumab, rVA576, and others
• Bullous Pemphigoid Therapeutic Assessment: Bullous Pemphigoid current marketed and Bullous Pemphigoid emerging therapies
• Bullous Pemphigoid Market Dynamics: Bullous Pemphigoid market drivers and Bullous Pemphigoid market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bullous Pemphigoid Unmet Needs, KOL's views, Analyst's views, Bullous Pemphigoid Market Access and Reimbursement
Discover more about therapies set to grab major Bullous Pemphigoid market share @ Bullous Pemphigoid Treatment Landscape
https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Bullous Pemphigoid Market Report Introduction
2. Executive Summary for Bullous Pemphigoid
3. SWOT analysis of Bullous Pemphigoid
4. Bullous Pemphigoid Patient Share (%) Overview at a Glance
5. Bullous Pemphigoid Market Overview at a Glance
6. Bullous Pemphigoid Disease Background and Overview
7. Bullous Pemphigoid Epidemiology and Patient Population
8. Country-Specific Patient Population of Bullous Pemphigoid
9. Bullous Pemphigoid Current Treatment and Medical Practices
10. Bullous Pemphigoid Unmet Needs
11. Bullous Pemphigoid Emerging Therapies
12. Bullous Pemphigoid Market Outlook
13. Country-Wise Bullous Pemphigoid Market Analysis (2020-2034)
14. Bullous Pemphigoid Market Access and Reimbursement of Therapies
15. Bullous Pemphigoid Market Drivers
16. Bullous Pemphigoid Market Barriers
17. Bullous Pemphigoid Appendix
18. Bullous Pemphigoid Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Bullous Pemphigoid Pipeline https://www.delveinsight.com/report-store/bullous-pemphigoid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Bullous Pemphigoid Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bullous Pemphigoid market. A detailed picture of the Bullous Pemphigoid pipeline landscape is provided, which includes the disease overview and Bullous Pemphigoid treatment guidelines.
Bullous Pemphigoid Epidemiology https://www.delveinsight.com/report-store/bullous-pemphigoid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Bullous Pemphigoid Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Bullous Pemphigoid epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bullous Pemphigoid Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | AstraZeneca, AKARI Therapeutics, Regeneron Pharmaceuticals, Argenx here
News-ID: 3579373 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Bullous
Bullous Keratopathy Market is expected to reach USD 755 million by 2034
Bullous keratopathy is a progressive corneal disorder characterized by corneal endothelial cell dysfunction, leading to corneal edema, blister-like formations, and painful vision loss. It is most commonly associated with aging, cataract surgery complications, and conditions such as Fuchs' endothelial dystrophy. Left untreated, bullous keratopathy can cause severe visual impairment, making it a significant cause of corneal blindness worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72223
As the global burden…
Bullous Pemphigoid Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Bullous pemphigoid (BP) is a rare, chronic, autoimmune blistering skin disorder that primarily affects the elderly population. Characterized by large, fluid-filled blisters, intense itching, and significant discomfort, BP is associated with immune system dysfunction, where antibodies attack proteins in the skin.
Although rare, its prevalence is rising due to aging populations, improved diagnostic accuracy, and increasing autoimmune disease incidence worldwide.
The global bullous pemphigoid market is gaining momentum as awareness grows…
Bullous Pemphigoid Market Projected to Witness Innovation in Autoimmune Therapie …
Bullous Pemphigoid Market Snapshot
The Bullous Pemphigoid Market is projected to grow at a CAGR of 5.8% during the forecast period 2025-2032.
Coherent Market Insights proudly presents its latest Bullous Pemphigoid Market Research Report, delivering a detailed examination of the U.S. Bullous Pemphigoid Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels, addressing evolving supply networks, payer-provider collaboration, and competitive strategies. As the…
Bullous Pemphigoid Treatment Market Size, Share, Analysis Report and Forecast 20 …
According to the report by Expert Market Research (EMR), the global bullous pemphigoid treatment market is being driven by the rising skin disease treatment market. Aided by rising skin disease treatment market and rising accessibility of healthcare facilities, the skin disease treatment market is expected to grow at a CAGR of 3% in the forecast period of 2024-2032.
Bullous pemphigoid is a chronic autoimmune skin disorder characterised by large, tense blisters…
Bullous Keratopathy Treatment Market Size, Share, Industry, Forecast and Outlook …
Bullous Keratopathy Treatment Market Overview
The global Bullous Keratopathy Treatment Market is anticipated to achieve a high Compound Annual Growth Rate (CAGR) during the forecast period from 2023 to 2030.
Bullous Keratopathy
Bullous keratopathy, also known as corneal edema, is characterized by the swelling of the cornea due to the failure of the corneal endothelium to maintain its transparent and dehydrated state. This condition often results from corneal endothelial dystrophy or trauma. The…
Bullous Pemphigoid Market 2020 Enhancement in Medical Sector
Bullous Pemphigoid - Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Bullous Pemphigoid Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This…
